News & Insights

• Leading medical journal, The Lancet, has published the findings of the 40,000 patient ORFAN study demonstrating the ability of Caristo’s CaRi-Heart FAI-Score to predict fatal and non-fatal cardiac events.
• Caristo’s AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients.

• Biofidelity has raised an internally led $24m funding round with support from existing investors including Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.
• The funding will support commerical rollout following the launch of its first product ASPYRE-Lung, a novel test that simplifies and accelerates the detection of biomarkers for non-small cell lung cancer.

James offers an insight into his 20+ years working with technology spinout companies from the University of Oxford.

• OQC has announced its ongoing $100m Series B, led by Japanese venture capital fund SBI Investment, in addition to existing investors Oxford Science Enterprises (OSE), University of Tokyo Edge Capital Partners (UTEC), and Lansdowne Partners.
• The announcement is made alongside the launch of OQC Toshiko the Company’s powerful next generation 32-qubit platform, deployed to commercial data-centres, enabling businesses to tap into ground-breaking technology from anywhere in the world, seamlessly and securely.

• OrganOx has raised £25m to continue the development and commercial rollout of metra, its fully automated normothermic perfusion (NMP) device for liver transplantation.
• The round was led by external investor Lauxera Capital Partners, with support from existing investors.